Clinical Trials

Information, research and clinical trials from affiliated physicians will be shown or listed on this page. Be sure to check back often for additional information and publications.

Qualified clinical research trial participants may receive:

  • No-cost medical evaluations and procedures

  • Study medication provided at no cost

  • Financial compensation

  • Convenient location and appointment times

  • Disease related education

  • Interested in participating? Search our clinical trials section
 
Clinical Trials
  


Clinical Trials:

2011-Present     QuERI Registry: Pulmonary Arterial Hypertension Quality Enhancement Initiative (QuERI) Extension Program.
PI – David N. Pham, MD. FCCP

2011-Present     Actelion - RESPIRE Registry: Registry to Prospectively Evaluate Use of Ventavis in Patients with Pulmonary Arterial Hypertension.
PI – David N. Pham, MD. FCCP

2011-Present     Actelion - PROSPECT Registry: Registry to PROSPECTively Describe Use of Epoprostenol of Injection ("RTS Epoprostenol") in Patients with Pulmonary Arterial Hypertension.
PI – David N. Pham, MD. FCCP

2011-Present     Cephalon – C38072/3081 – A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma. Contract Pending.
PI – David N. Pham, MD. FCCP

2010-Present    HZC113782: Phase III. A Clinical Outcomes Study to comare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardio vascular disease.
PI – David N. Pham, MD. FCCP

2009-Present     Bayer - BAY-63-2521/14308: Randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the hemodynamic effect of Riociguat (BAY 63-2521) as well as safety and kinectics in patients with pulmonary hypertension associated with left ventricular systolic dysfunction.
PI – David N. Pham, MD. FCCP

2010-Present     Pfizer – PF00489791 – A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Parallel Group Study Investigating the Dose-Response of PH00489791 on Acute Hemodynamics in subject with idiopatic and familial Pulmonary Arterial Hypertension.
PI – David N. Pham, MD. FCCP

2009-Present     Genetech – ILR4646g – A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MILR1444A in Adult Asthmatics Who Are Inadequately Controlled on Inhaled Steroids. Contract Pending.
PI – David N. Pham, MD. FCCP

2009-Present     Pfizer B1321001 – A Phase III, Multiple-Center, Randomized, Double Blind, Placebo Controlled, Safety and Efficacy Study of Sitaxsentan sodium in Subjects with Pulmonary Arterial Hypertension.
PI – David N. Pham, MD, FCCP

2009-Present     Pfizer B1321002: A Phase 3, Multi-Center, Open Label Study to Evaluate the Long-Term Safety of Sitaxsentan Sodium in Patients with Pulmonary Arterial Hypertension.
PI – David N. Pham, MD, FCCP

2009-Present     Pfizer B1321002: A Randomized, Double-Blind, Efficacy and Safety Study of Monotherapy Sitaxsentan Sodium versus Combination Therapy with Sitaxsentan Sodium and Sildenafil Citrate in Patients with Pulmonary Arterial Hypertension who have completed study B1321001. Contract Pending.
PI – David N. Pham, MD, FCCP

2009- Present     Novartis – A Phase III double blind, double-dummy, 52 week study to assess the safety of treatment with QMF Twisthaler® (x/400 µg and x/800 µg QD PM) and fluticasone propionate/salmeterol via MDDPI (250/50 µg and 500/50 µg BID) in adults with COPD. Contracting Pending.
PI – David N. Pham, MD, FCCP

2009-Present     Novartis – A Randomized, double-blind, controlled, parallel group, 12 week treatment study to compare efficacy and safety of the combination of indacaterol 150 microgram once daily with open label tiotropium 18 microgram once daily in patients with moderate-to-severe chronic obstructive pulmonary disease.
PI – David N. Pham, MD, FCCP
 

  
 
Research publications
  

2008 - Present     Boehringer-Ingelheim - A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (5 μg/day) over 48 weeks as add-on controller therapy on top of usual care in patients with severe persistent asthma.
PI – David N. Pham, MD, FCCP

2008 - Present     GlaxoSmithKlein - Phase: IIb To evaluate the efficacy and safety of GSK233705 long-acting muscarinic antagonist bronchodilator once per day.
PI – David N. Pham, MD, FCCP

2008 – Present     Genentech – A randomized, Placebo-Controlled, Prospective Investigator, Parallel Group 24 week clinical trial to compare the effect of Xolair and Placebo in subjects with Chronic Obstructive pulmonary Disease (COPD) with hyperreactive responsiveness, elevated IGE, and perineal allergies and lung function.
PI – David N. Pham, MD, FCCP
PI - Russell Bowler, MD
National Jewish Medical and Research Center

2007- Present     Genentech - Xolair for Moderate to Severe Asthma Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled study of Xolair in subjects with moderate to severe persistent asthma who are inadequately controlled with high dose inhaled corticosteroids and long-acting beta-agonists
PI – David Pham, MD, FCCP

 

  
       
       
     
     
     

 

Copyright 2010 © Lung Care Center. All rights reserved.